Regeneron Announced 89% Estimated Event-free Survival At One Year Among Patients With Stage II To IV Resectable Cutaneous Squamous Cell Carcinoma Who Received Libtayo Prior To Surgery In A Phase 2 Trial
Portfolio Pulse from Charles Gross
Regeneron Pharmaceuticals announced key secondary endpoints for Libtayo as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma. The results from a Phase 2 trial showed 89% estimated event-free survival at one year among patients who received Libtayo prior to surgery. No disease recurrence was observed among the 51% of patients who experienced a pathologic complete response.
October 21, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's successful Phase 2 trial results for Libtayo could potentially boost the company's stock in the short term.
The positive results from the Phase 2 trial of Libtayo indicate a potential increase in the drug's usage, which could lead to increased revenues for Regeneron. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100